Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.13Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic tone: the company reports a strong cash position with multi-year runway, notable reductions in burn, positive clinical signals (especially in the AB-clear precision-medicine subgroup) and constructive regulatory engagement with the FDA. However, the CHMP negative opinion, a missed ADCS-ADL endpoint in the original EU submission, and remaining execution and regulatory obligations (including potential confirmatory post-approval studies) are meaningful near-term risks. Overall, positive operational and scientific developments outweigh the regulatory setbacks, but outcomes remain contingent on ongoing reexamination and further regulatory interactions.Company Guidance
Strong cash position and runway
Cash of $131.7 million at Dec 31 with no debt; cash used in operating activities of $7.1 million during the quarter; company anticipates cash runway of more than three years at current burn rate.
Significant reduction in operating expenses
R&D expenses decreased to $4.7 million from $10.4 million year-over-year (≈ -54.8%); G&A decreased to $2.1 million from $3.1 million year-over-year (≈ -32.3%), driven by completion of a large blarcamesine manufacturing campaign and reduced clinical activity after completion of Anavex 3-71 Phase II.
Manageable reported loss for the quarter
Reported net loss of $5.7 million for the quarter, or $0.06 per share, consistent with lower cash utilization and expense reductions.
Positive clinical and scientific readouts presented
Late-breaking communication at CTAD affirmed identified precision-medicine patient population, reporting significant clinical and quality-of-life improvements in early Alzheimer’s disease; company cites highly clinically meaningful effect sizes (stated as ~2–3x larger than many competitors) in the AB-clear population.
Active regulatory engagement with FDA
Received feedback from an FDA Type C meeting; FDA indicated pathway options and requested submission of existing Phase 2b/3 (Anavex 2-73 AD-004) data to support next steps and potential NDA discussions.
Strategic collaborations and pipeline advancement
Participation as an industry partner in the EU-funded Access AD initiative (blarcamesine to be evaluated in a clinical prediction study); advancement plans for Anavex 3-71 toward pivotal clinical studies for schizophrenia-related disorders; multiple planned/underway publications and conference presentations on biomarkers, AB-clear population, collagen 24A1, and fragile X findings.
AVXL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AVXL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 09, 2026 | $4.10 | $4.35 | +6.10% |
Nov 25, 2025 | $3.08 | $3.46 | +12.34% |
Aug 12, 2025 | $11.35 | $10.78 | -5.02% |
May 13, 2025 | $8.55 | $8.12 | -5.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Anavex Life Sciences (AVXL) report earnings?
Anavex Life Sciences (AVXL) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Anavex Life Sciences (AVXL) earnings time?
Anavex Life Sciences (AVXL) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVXL EPS forecast?
AVXL EPS forecast for the fiscal quarter 2026 (Q2) is -0.08.
